HC Wainwright Reaffirms Buy Rating for TScan Therapeutics (NASDAQ:TCRX)

HC Wainwright restated their buy rating on shares of TScan Therapeutics (NASDAQ:TCRX) in a research report report published on Friday,Benzinga reports. HC Wainwright currently has a $15.00 price target on the stock.

A number of other brokerages have also commented on TCRX. Wedbush reiterated an “outperform” rating and issued a $10.00 price target on shares of TScan Therapeutics in a research note on Tuesday, November 5th. Needham & Company LLC reissued a “buy” rating and set a $11.00 target price on shares of TScan Therapeutics in a research report on Tuesday. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $12.00.

TScan Therapeutics Stock Down 8.5 %

Shares of TCRX stock traded down $0.41 during midday trading on Friday, reaching $4.41. 244,150 shares of the stock were exchanged, compared to its average volume of 246,912. TScan Therapeutics has a 1 year low of $3.73 and a 1 year high of $9.69. The firm has a market cap of $233.62 million, a PE ratio of -4.16 and a beta of 0.79. The company’s 50 day moving average is $5.31 and its two-hundred day moving average is $6.49. The company has a current ratio of 9.56, a quick ratio of 7.77 and a debt-to-equity ratio of 0.13.

Insider Activity at TScan Therapeutics

In related news, Director Barbara Klencke acquired 5,000 shares of the stock in a transaction dated Monday, August 26th. The stock was acquired at an average cost of $5.53 per share, for a total transaction of $27,650.00. Following the completion of the purchase, the director now owns 40,000 shares of the company’s stock, valued at approximately $221,200. This represents a 14.29 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Zoran Zdraveski sold 164,686 shares of the firm’s stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $5.78, for a total value of $951,885.08. Following the completion of the transaction, the insider now owns 4,716 shares of the company’s stock, valued at approximately $27,258.48. The trade was a 97.22 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders bought 15,000 shares of company stock worth $82,550. Company insiders own 2.76% of the company’s stock.

Hedge Funds Weigh In On TScan Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of the business. Geode Capital Management LLC raised its holdings in TScan Therapeutics by 8.1% in the 3rd quarter. Geode Capital Management LLC now owns 973,466 shares of the company’s stock valued at $4,849,000 after acquiring an additional 72,967 shares during the last quarter. Barclays PLC increased its holdings in TScan Therapeutics by 341.1% in the third quarter. Barclays PLC now owns 58,067 shares of the company’s stock valued at $289,000 after buying an additional 44,903 shares during the last quarter. XTX Topco Ltd purchased a new stake in TScan Therapeutics in the third quarter valued at $112,000. Wellington Management Group LLP grew its position in shares of TScan Therapeutics by 38.9% during the third quarter. Wellington Management Group LLP now owns 126,345 shares of the company’s stock worth $629,000 after acquiring an additional 35,404 shares during the last quarter. Finally, State Street Corp grew its stake in shares of TScan Therapeutics by 24.4% in the 3rd quarter. State Street Corp now owns 756,499 shares of the company’s stock valued at $3,767,000 after purchasing an additional 148,414 shares during the last quarter. Hedge funds and other institutional investors own 82.83% of the company’s stock.

About TScan Therapeutics

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.